Companies › DiaMedica Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DM199 Recombinant human tissue kallikrein (rinvecalinase alfa) - serine protease that activates | KLKB1 | Phase 2 | Acute Stroke | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05065216 | DM199 | Phase 2 | Acute Stroke | Neurology | Dec 2026 |
Cash and short-term investments of $44m on 2026-06-30; operating cash outflow about $35m a year; runway about 15 months at that burn, to Sep 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands
Satellos Bioscience Coya Therapeutics PepGen Cognition Therapeutics IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.